Articles

The prevalence of transthyretin cardiac amyloidosis was nearly 28% in patients diagnosed with heart failure with preserved ejection fraction who have ≥2 red flags for cardiac amyloidosis. Read More ›

Recognizing critical differences in genotype and phenotype among patients with transthyretin amyloidosis or other inherited cardiovascular diseases is imperative for optimal outcomes. Read More ›


Amyloidosis identified as the cause of heart failure in nearly 1 in 10 internal medicine patients. Read More ›

Quantitative 99mTc-PYP imaging has potential as a marker of disease burden by providing robust evaluation in patients with transthyretin amyloid cardiomyopathy. Read More ›

Increased clinical vigilance is warranted as the underrecognized phenotype of transthyretin cardiac amyloidosis is associated with worse clinical outcomes. Read More ›

Providers face challenges with clinical vigilance and treatment for transthyretin amyloidosis due to the range of disease severity and phenotypic penetrance of carriers of variant forms. Read More ›

Researchers have found that cardiac scintigraphy imaging performance may be improved for uncovering transthyretin cardiac amyloidosis using deep learning augmentation of interpretation. Read More ›

Early diagnosis before the development of advanced organ disease remains key in improving outcomes in amyloidosis. Read More ›

A case series highlights how prognosis worsens and options for treatment are limited, once cardiac involvement is extensive in cardiac amyloidosis. Read More ›

Page 5 of 14

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.